These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 23410826)

  • 21. Evaluation of microRNA expression profiles that may predict recurrence of localized stage I non-small cell lung cancer after surgical resection.
    Patnaik SK; Kannisto E; Knudsen S; Yendamuri S
    Cancer Res; 2010 Jan; 70(1):36-45. PubMed ID: 20028859
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Characterization of the MicroRNA Cargo of Extracellular Vesicles Isolated from a Pulmonary Tumor-Draining Vein Identifies miR-203a-3p as a Relapse Biomarker for Resected Non-Small Cell Lung Cancer.
    Han B; Molins L; He Y; Viñolas N; Sánchez-Lorente D; Boada M; Guirao A; Díaz T; Martinez D; Ramirez J; Moisés J; Acosta-Plasencia M; Monzo M; Marrades RM; Navarro A
    Int J Mol Sci; 2022 Jun; 23(13):. PubMed ID: 35806142
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Significance of Serum MicroRNAs in the Auxiliary Diagnosis of Non-Small Cell Lung Cancer.
    Shi GL; Chen Y; Sun Y; Yin YJ; Song CX
    Clin Lab; 2017 Jan; 63(1):133-140. PubMed ID: 28164492
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Upregulation of serum miR-494 predicts poor prognosis in non-small cell lung cancer patients.
    Zhang J; Wang T; Zhang Y; Wang H; Wu Y; Liu K; Pei C
    Cancer Biomark; 2018; 21(4):763-768. PubMed ID: 29286916
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Circulating exosomal microRNAs as prognostic biomarkers for non-small-cell lung cancer.
    Liu Q; Yu Z; Yuan S; Xie W; Li C; Hu Z; Xiang Y; Wu N; Wu L; Bai L; Li Y
    Oncotarget; 2017 Feb; 8(8):13048-13058. PubMed ID: 28055956
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Serum miR-223: A Validated Biomarker for Detection of Early-Stage Non-Small Cell Lung Cancer.
    D'Antona P; Cattoni M; Dominioni L; Poli A; Moretti F; Cinquetti R; Gini E; Daffrè E; Noonan DM; Imperatori A; Rotolo N; Campomenosi P
    Cancer Epidemiol Biomarkers Prev; 2019 Nov; 28(11):1926-1933. PubMed ID: 31488416
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Aberrant miR-181b-5p and miR-486-5p expression in serum and tissue of non-small cell lung cancer.
    Tian F; Shen Y; Chen Z; Li R; Lu J; Ge Q
    Gene; 2016 Oct; 591(2):338-43. PubMed ID: 27291819
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Plasma circulating microRNA-944 and microRNA-3662 as potential histologic type-specific early lung cancer biomarkers.
    Powrózek T; Krawczyk P; Kowalski DM; Winiarczyk K; Olszyna-Serementa M; Milanowski J
    Transl Res; 2015 Oct; 166(4):315-23. PubMed ID: 26079400
    [TBL] [Abstract][Full Text] [Related]  

  • 29. miR-141 and miR-200c as markers of overall survival in early stage non-small cell lung cancer adenocarcinoma.
    Tejero R; Navarro A; Campayo M; Viñolas N; Marrades RM; Cordeiro A; Ruíz-Martínez M; Santasusagna S; Molins L; Ramirez J; Monzó M
    PLoS One; 2014; 9(7):e101899. PubMed ID: 25003366
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Identification of differentially expressed circulating serum microRNA for the diagnosis and prognosis of Indian non-small cell lung cancer patients.
    Kumar S; Sharawat SK; Ali A; Gaur V; Malik PS; Kumar S; Mohan A; Guleria R
    Curr Probl Cancer; 2020 Aug; 44(4):100540. PubMed ID: 32007320
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A novel circulating miRNA-based signature for the early diagnosis and prognosis prediction of non-small-cell lung cancer.
    Zhou C; Chen Z; Zhao L; Zhao W; Zhu Y; Liu J; Zhao X
    J Clin Lab Anal; 2020 Nov; 34(11):e23505. PubMed ID: 33463758
    [TBL] [Abstract][Full Text] [Related]  

  • 32. SULF2 Expression Is a Potential Diagnostic and Prognostic Marker in Lung Cancer.
    Lui NS; Yang YW; van Zante A; Buchanan P; Jablons DM; Lemjabbar-Alaoui H
    PLoS One; 2016; 11(2):e0148911. PubMed ID: 26882224
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Up-Regulation of miR-21 Expression Predicate Advanced Clinicopathological Features and Poor Prognosis in Patients with Non-Small Cell Lung Cancer.
    Tian L; Shan W; Zhang Y; Lv X; Li X; Wei C
    Pathol Oncol Res; 2016 Jan; 22(1):161-7. PubMed ID: 26453197
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A circulating non-coding RNA panel as an early detection predictor of non-small cell lung cancer.
    Peng H; Wang J; Li J; Zhao M; Huang SK; Gu YY; Li Y; Sun XJ; Yang L; Luo Q; Huang CZ
    Life Sci; 2016 Apr; 151():235-242. PubMed ID: 26946307
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Elevated expression of miR-24-3p is a potentially adverse prognostic factor in colorectal adenocarcinoma.
    Kerimis D; Kontos CK; Christodoulou S; Papadopoulos IN; Scorilas A
    Clin Biochem; 2017 Apr; 50(6):285-292. PubMed ID: 27939727
    [TBL] [Abstract][Full Text] [Related]  

  • 36. miR-126-3p and miR-451a correlate with clinicopathological features of lung adenocarcinoma: The underlying molecular mechanisms.
    Chen Q; Hu H; Jiao D; Yan J; Xu W; Tang X; Chen J; Wang J
    Oncol Rep; 2016 Aug; 36(2):909-17. PubMed ID: 27277197
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Plasma miRNAs in predicting radiosensitivity in non-small cell lung cancer.
    Chen X; Xu Y; Liao X; Liao R; Zhang L; Niu K; Li T; Li D; Chen Z; Duan Y; Sun J
    Tumour Biol; 2016 Sep; 37(9):11927-11936. PubMed ID: 27075472
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic implication of methylation-based circulating tumor DNA detection prior to surgery in stage I non-small cell lung cancer.
    Bossé Y; Dasgupta A; Abadier M; Guthrie V; Song F; Saavedra Armero V; Gaudreault N; Orain M; Lamaze FC; Melton C; Nance T; Hung T; Hodgson D; Abbosh C; Joubert P
    Cancer Lett; 2024 Jul; 594():216984. PubMed ID: 38797230
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Circulating miR-21-5p and miR-126-3p: diagnostic, prognostic value, and multivariate analysis in non-small-cell lung cancer.
    Soliman SE; Abdelaleem AH; Alhanafy AM; Ibrahem RAL; Elhaded ASA; Assar MFA
    Mol Biol Rep; 2021 Mar; 48(3):2543-2552. PubMed ID: 33837901
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A MicroRNA cluster at 14q32 drives aggressive lung adenocarcinoma.
    Nadal E; Zhong J; Lin J; Reddy RM; Ramnath N; Orringer MB; Chang AC; Beer DG; Chen G
    Clin Cancer Res; 2014 Jun; 20(12):3107-17. PubMed ID: 24833665
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.